Daily Care for February 5, 2020
advertisement
- Impact of flash glucose monitoring on glycaemic control and quality of life in patients with type 1 diabetes: A 18-month follow-up in real life (HTML)
- Quality of Life and Glucose Control After 1 Year of Nationwide Reimbursement of Intermittently Scanned Continuous Glucose Monitoring in Adults Living With Type 1 Diabetes (FUTURE): A Prospective Observational Real-World Cohort Study
- First Approval for Fast-Acting Lispro for Diabetes; EU OKs Oral Semaglutide
- New ADA Standards: Promoting Health (Requires free Medscape registration)
- Risk Factors for First and Subsequent CVD Events in Type 1 Diabetes: The DCCT/EDIC Study (HTML)
- Barriers and Facilitators to Involvement in Children’s Diabetes Management Among Minority Parents (HTML)
- Health professionals’ views about who would benefit from using a closed-loop system: a qualitative study (HTML)
- FDA: US metformin products safe from NDMA contamination
- Can Short Bouts of Exercise (“Exercise Snacks”) Improve Body Composition in Adolescents with Type 1 Diabetes? A Feasibility Study (HTML)
- Increased time in range and improved insulin adherence after introduction of a smart connected insulin pen (HTML)
- Long-term effects of continuous subcutaneous insulin infusion in adults with type 1 diabetes mellitus patients: Results of a public healthcare system
- Efficacy and Safety of Treatment with New Basal Insulin Analogues in Type 1 Diabetes: Nation-Wide Survey (HTML)
- Overweight and obese children with optimal control in the T1D Exchange Registry: How are they different from lean children with optimal control? (HTML)
- An Examination of Sex Differences in a Disease-Specific Model of Disordered Eating Behaviors in Type 1 Diabetes
- Respective Contributions of Glycemic Variability and Mean Daily Glucose as Predictors of Hypoglycemia in Type 1 Diabetes: Are They Equivalent? (HTML)
- Substance Use Among Adolescents and Young Adults With Type 1 Diabetes: Discussions in Routine Diabetes Care (HTML)
- Estimation of Medicare Part D Spending on Insulin for Patients With Diabetes Using Negotiated Prices and a Defined Formulary
